Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

InMed Pharmaceuticals (INM) Gross Profit (2021 - 2025)

InMed Pharmaceuticals has reported Gross Profit over the past 5 years, most recently at $184194.0 for Q4 2025.

  • For Q4 2025, Gross Profit fell 60.04% year-over-year to $184194.0; the TTM value through Dec 2025 reached $1.3 million, down 21.65%, while the annual FY2025 figure was $1.7 million, 55.02% up from the prior year.
  • Gross Profit for Q4 2025 was $184194.0 at InMed Pharmaceuticals, down from $403159.0 in the prior quarter.
  • Over five years, Gross Profit peaked at $1.6 million in Q2 2023 and troughed at -$491018.0 in Q3 2022.
  • A 5-year average of $314202.0 and a median of $249714.0 in 2022 define the central range for Gross Profit.
  • On a YoY basis, Gross Profit climbed as much as 2222.82% in 2024 and fell as far as 70.32% in 2024.
  • Year by year, Gross Profit stood at $111555.0 in 2021, then grew by 17.58% to $131163.0 in 2022, then skyrocketed by 147.13% to $324142.0 in 2023, then surged by 42.19% to $460894.0 in 2024, then crashed by 60.04% to $184194.0 in 2025.
  • Business Quant data shows Gross Profit for INM at $184194.0 in Q4 2025, $403159.0 in Q3 2025, and $576654.0 in Q2 2025.